Condition: Gastric Cancer · Esophagogastric Junction Adenocarcinoma · Sponsor: Zekuan Xu
This Phase II clinical study is a prospective, open-label, single-arm trial designed to evaluate the efficacy and safety of combining anti-PD-1 therapy (Serplulimab) with thymalfasin and the SOX chemotherapy regimen as a neoadjuvant treatment for patients with clinical stage III gastric or gastroesophageal junction(GEJ) adenocarcinoma.
This description comes directly from the study's public registry record.
Hao Xu, MD · +86 13851530117 · hxu@njmu.edu.cn
Hongda Liu, MD · +86 17521597055 · Liuhongda@njmu.edu.cn
Always discuss trial participation with your own doctor first.
| The First Hospital of Nanjing Medical University | Nanjing, Jiangsu, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06461910